Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
Quick Facts
What This Study Found
Optimized triagonists normalized body weight in DIO mice and enhanced energy expenditure more than GLP-1R mono-agonists.
Key Numbers
How They Did This
The study involved designing unimolecular peptide triagonists and testing their effects on weight, food intake, glucose control, and energy expenditure in diet-induced obese (DIO) mice.
Why This Research Matters
This research highlights a promising approach to obesity treatment by targeting multiple hormonal pathways. Understanding how these peptides work could lead to more effective therapies for weight management.
What This Study Doesn't Tell Us
The study is based on preclinical models, so results may not directly translate to humans.
Trust & Context
- Original Title:
- Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
- Published In:
- Molecular metabolism, 63, 101533 (2022)
- Authors:
- Knerr, Patrick J(3), Mowery, Stephanie A(2), Douros, Jonathan D(5), Premdjee, Bhavesh, Hjøllund, Karina Rahr, He, Yantao, Kruse Hansen, Ann Maria, Olsen, Anette K, Perez-Tilve, Diego, DiMarchi, Richard D, Finan, Brian
- Database ID:
- RPEP-06257
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06257APA
Knerr, Patrick J; Mowery, Stephanie A; Douros, Jonathan D; Premdjee, Bhavesh; Hjøllund, Karina Rahr; He, Yantao; Kruse Hansen, Ann Maria; Olsen, Anette K; Perez-Tilve, Diego; DiMarchi, Richard D; Finan, Brian. (2022). Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.. Molecular metabolism, 63, 101533. https://doi.org/10.1016/j.molmet.2022.101533
MLA
Knerr, Patrick J, et al. "Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.." Molecular metabolism, 2022. https://doi.org/10.1016/j.molmet.2022.101533
RethinkPeptides
RethinkPeptides Research Database. "Next generation GLP-1/GIP/glucagon triple agonists normalize..." RPEP-06257. Retrieved from https://rethinkpeptides.com/research/knerr-2022-next-generation-glp1gipglucagon-triple
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.